What is the ROE (Return on Equity) of OncoCyte this year?
The ROE of OncoCyte this year is -1.12 undefined.
OncoCyte ROE 2024
OncoCyte ROE
-1.12
Ticker
OCX
ISIN
US68235C1071
WKN
A2ACBH
In 2024, OncoCyte's return on equity (ROE) was -1.12, a -39.47% increase from the -1.85 ROE in the previous year.
OncoCyte Aktienanalyse
What does OncoCyte do?
OncoCyte Corp is a company based in Alameda, California, that is involved in the field of cancer diagnostics. It was founded in 2009 with the goal of developing and commercializing innovative solutions for cancer diagnosis. The business model of OncoCyte Corp is based on the development and marketing of diagnostic tests for various types of cancer. The company focuses on identifying biomarkers that enable accurate and reliable diagnosis. The tests developed by OncoCyte Corp can be used for both early detection and monitoring of cancer patients. OncoCyte Corp is divided into several divisions, each specialized in developing products for specific types of cancer. These divisions include breast cancer, lung cancer, bladder cancer, and ovarian cancer. Each division is led by an expert team with extensive knowledge and experience in the respective area. One of the key products of OncoCyte Corp is the DetermaRx™ test, specifically developed for lung cancer. This test identifies specific biomarkers that provide a prognosis regarding the response to chemotherapy. The DetermaRx™ test is currently in clinical trials and could be used in the future to aid in the decision-making process for selecting the appropriate treatment method for lung cancer patients. Another product of OncoCyte Corp is the DetermaDx™ test, specifically developed for the early detection of breast cancer. This test utilizes a combination of biomarker-based tests and imaging techniques to detect cancer cells at an early stage. The DetermaDx™ test is currently undergoing validation and could potentially become a standard diagnosis for breast cancer in the future. OncoCyte Corp has also formed several partnerships with pharmaceutical and diagnostic companies to promote the development and commercialization of its products. One such partnership exists with Life Technologies Corporation, a globally leading company in the field of diagnostics and analytics. OncoCyte Corp strives to develop and bring to market innovative solutions for cancer diagnosis. With its vast resources and experienced team of scientists, the company has the potential to change the way cancer is diagnosed and treated. OncoCyte ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding OncoCyte's Return on Equity (ROE)
OncoCyte's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing OncoCyte's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
OncoCyte's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in OncoCyte’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about OncoCyte stock
How has the Return on Equity (ROE) of OncoCyte developed compared to the previous year?
The ROE of OncoCyte has increased by -39.47% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of OncoCyte?
A high ROE indicates that OncoCyte generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of OncoCyte?
A low ROE can indicate that OncoCyte is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of OncoCyte affect the company?
A change in ROE (Return on Equity) of OncoCyte can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of OncoCyte?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of OncoCyte?
Some factors that can influence OncoCyte's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does OncoCyte pay?
Over the past 12 months, OncoCyte paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, OncoCyte is expected to pay a dividend of 0 USD.
What is the dividend yield of OncoCyte?
The current dividend yield of OncoCyte is .
When does OncoCyte pay dividends?
OncoCyte pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of OncoCyte?
OncoCyte paid dividends every year for the past 0 years.
What is the dividend of OncoCyte?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is OncoCyte located?
OncoCyte is assigned to the 'Health' sector.
Wann musste ich die Aktien von OncoCyte kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of OncoCyte from 9/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/28/2024.
When did OncoCyte pay the last dividend?
The last dividend was paid out on 9/28/2024.
What was the dividend of OncoCyte in the year 2023?
In the year 2023, OncoCyte distributed 0 USD as dividends.
In which currency does OncoCyte pay out the dividend?
The dividends of OncoCyte are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von OncoCyte
Our stock analysis for OncoCyte Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OncoCyte Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
